Tags

Type your tag names separated by a space and hit enter

Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
J Dermatolog Treat. 2005 Feb; 16(1):31-6.JD

Abstract

BACKGROUND

Scalp involvement in psoriatic patients represents a common issue. Treatment of the hairy skin requires adequate pharmaceutical formulations; hence, a new specific shampoo formulation of clobetasol propionate 0.05% was developed by Galderma R&D, Inc.

METHODS

For this multicenter, randomized, investigator-masked, parallel group study, 151 subjects with moderate to severe scalp psoriasis were randomized to 4 weeks of treatment with clobetasol propionate shampoo or calcipotriol solution.

RESULTS

Clobetasol propionate demonstrated significantly superior efficacy to calcipotriol solution (total severity score: mean difference 0.51, 95% CI 0.05-0.97, p = 0.028; global severity score: mean difference 0.43, 95% CI 0.08-0.78, p = 0.016). Adverse events were more common in the calcipotriol group than in the clobetasol propionate shampoo group. Telangiectasia and skin atrophy did not differ significantly between treatments; however, a burning sensation was significantly more common in the calcipotriol solution group.

CONCLUSIONS

Short contact therapy of scalp psoriasis with this new shampoo formulation of clobetasol propionate was significantly more effective and better tolerated than calcipotriol solution for the treatment of scalp psoriasis.

Authors+Show Affiliations

Reygagne P
Centre Sabouraud, Paris, France.
Mrowietz U
No affiliation info available
Decroix J
No affiliation info available
de Waard-van der Spek FB
No affiliation info available
Acebes LO
No affiliation info available
Figueiredo A
No affiliation info available
Caputo R
No affiliation info available
Poncet M
No affiliation info available
Arsonnaud S
No affiliation info available

MeSH

Administration, TopicalAdultCalcitriolClobetasolDermatologic AgentsFemaleHair PreparationsHumansMaleMiddle AgedPsoriasisScalp DermatosesSeverity of Illness IndexSolutionsTreatment Outcome

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15897165

Citation

Reygagne, P, et al. "Clobetasol Propionate Shampoo 0.05% and Calcipotriol Solution 0.005%: a Randomized Comparison of Efficacy and Safety in Subjects With Scalp Psoriasis." The Journal of Dermatological Treatment, vol. 16, no. 1, 2005, pp. 31-6.
Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16(1):31-6.
Reygagne, P., Mrowietz, U., Decroix, J., de Waard-van der Spek, F. B., Acebes, L. O., Figueiredo, A., Caputo, R., Poncet, M., & Arsonnaud, S. (2005). Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. The Journal of Dermatological Treatment, 16(1), 31-6.
Reygagne P, et al. Clobetasol Propionate Shampoo 0.05% and Calcipotriol Solution 0.005%: a Randomized Comparison of Efficacy and Safety in Subjects With Scalp Psoriasis. J Dermatolog Treat. 2005;16(1):31-6. PubMed PMID: 15897165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. AU - Reygagne,P, AU - Mrowietz,U, AU - Decroix,J, AU - de Waard-van der Spek,F B, AU - Acebes,L Olmos, AU - Figueiredo,A, AU - Caputo,R, AU - Poncet,M, AU - Arsonnaud,S, PY - 2005/5/18/pubmed PY - 2005/6/10/medline PY - 2005/5/18/entrez SP - 31 EP - 6 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 16 IS - 1 N2 - BACKGROUND: Scalp involvement in psoriatic patients represents a common issue. Treatment of the hairy skin requires adequate pharmaceutical formulations; hence, a new specific shampoo formulation of clobetasol propionate 0.05% was developed by Galderma R&D, Inc. METHODS: For this multicenter, randomized, investigator-masked, parallel group study, 151 subjects with moderate to severe scalp psoriasis were randomized to 4 weeks of treatment with clobetasol propionate shampoo or calcipotriol solution. RESULTS: Clobetasol propionate demonstrated significantly superior efficacy to calcipotriol solution (total severity score: mean difference 0.51, 95% CI 0.05-0.97, p = 0.028; global severity score: mean difference 0.43, 95% CI 0.08-0.78, p = 0.016). Adverse events were more common in the calcipotriol group than in the clobetasol propionate shampoo group. Telangiectasia and skin atrophy did not differ significantly between treatments; however, a burning sensation was significantly more common in the calcipotriol solution group. CONCLUSIONS: Short contact therapy of scalp psoriasis with this new shampoo formulation of clobetasol propionate was significantly more effective and better tolerated than calcipotriol solution for the treatment of scalp psoriasis. SN - 0954-6634 UR - https://www.unboundmedicine.com/medline/citation/15897165/Clobetasol_propionate_shampoo_0_05_and_calcipotriol_solution_0_005:_a_randomized_comparison_of_efficacy_and_safety_in_subjects_with_scalp_psoriasis_ DB - PRIME DP - Unbound Medicine ER -